お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
192431

先端巨大症:パイプライン製品の分析

Acromegaly - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 96 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
先端巨大症:パイプライン製品の分析
出版日: 2020年09月30日
発行: Global Markets Direct
ページ情報: 英文 96 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

先端巨大症は、成人期に下垂体で成長ホルモンが過剰に生成される場合に発症するホルモン障害です。体臭、疲れやすい、頭痛、巨大な足、過剰な身長、関節周囲の骨の部位の腫れ、歯の間隔が広い、睡眠時無呼吸などの症状が見られます。治療には、外科手術、ドーパミン作動薬、成長ホルモン拮抗薬などが含まれます。

当レポートでは、先端巨大症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

先端巨大症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Aegis Therapeutics, LLC
  • Antisense Therapeutics Limited
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • DexTech Medical AB
  • Foresee Pharmaceuticals, LLC
  • Glide Pharmaceutical Technologies Limited
  • Ionis Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Italfarmaco S.p.A.
  • Novartis AG
  • Peptron, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ATL-1103
  • BIM-23A758
  • COR-005
  • FP-002
  • G-02113
  • ISIS-GHRLRx
  • ITF-2984
  • L-779976
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate long acting
  • octreotide acetate SR
  • octreotide SR
  • pasireotide ER
  • Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors
  • Somadex
  • SXN-101742
  • SXN-101959

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Acromegaly, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Acromegaly - Pipeline by Antisense Therapeutics Ltd, H2 2020
  • Acromegaly - Pipeline by Aquestive Therapeutics Inc, H2 2020
  • Acromegaly - Pipeline by Ascil Proyectos SL, H2 2020
  • Acromegaly - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
  • Acromegaly - Pipeline by Camurus AB, H2 2020
  • Acromegaly - Pipeline by Chiasma Inc, H2 2020
  • Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H2 2020
  • Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020
  • Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H2 2020
  • Acromegaly - Pipeline by DexTech Medical AB, H2 2020
  • Acromegaly - Pipeline by Enesi Pharma Ltd, H2 2020
  • Acromegaly - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2020
  • Acromegaly - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2020
  • Acromegaly - Pipeline by GlyTech Inc, H2 2020
  • Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H2 2020
  • Acromegaly - Pipeline by Italfarmaco SpA, H2 2020
  • Acromegaly - Pipeline by OPKO Health Inc, H2 2020
  • Acromegaly - Pipeline by Pharmathen Global BV, H2 2020
  • Acromegaly - Pipeline by Strongbridge Biopharma plc, H2 2020
  • Acromegaly - Dormant Projects, H2 2020
  • Acromegaly - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Acromegaly, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12558IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 4, 4, 3 and 1 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Acromegaly - Overview
  • Acromegaly - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Acromegaly - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Acromegaly - Companies Involved in Therapeutics Development
  • Antisense Therapeutics Ltd
  • Aquestive Therapeutics Inc
  • Ascil Proyectos SL
  • Auritec Pharmaceuticals Inc
  • Camurus AB
  • Chiasma Inc
  • Crinetics Pharmaceuticals Inc
  • Daewoong Pharmaceutical Co Ltd
  • Dauntless Pharmaceuticals Inc
  • DexTech Medical AB
  • Enesi Pharma Ltd
  • Foresee Pharmaceuticals Co Ltd
  • GeneScience Pharmaceuticals Co Ltd
  • GlyTech Inc
  • Ionis Pharmaceuticals Inc
  • Italfarmaco SpA
  • OPKO Health Inc
  • Pharmathen Global BV
  • Strongbridge Biopharma plc
  • Acromegaly - Drug Profiles
  • atesidorsen sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DP-2018 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IONIS-GHRLRx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ITF-2984 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lanreotide SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MOD-12014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide acetate CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide acetate DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide acetate microspheres - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide LA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide LA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • octreotide SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • paltusotine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Somadex - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veldoreotide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veldoreotide IR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Acromegaly - Dormant Projects
  • Acromegaly - Discontinued Products
  • Acromegaly - Product Development Milestones
  • Featured News & Press Releases
  • Sep 04, 2020: Crinetics Pharmaceuticals provides new data from Paltusotine and ACTH antagonist development programs at European Congress of Endocrinology
  • Aug 31, 2020: Chiasma announces U.S. commercial launch and availability of MYCAPSSA, the first and only oral somatostatin analog for patients with acromegaly
  • Aug 17, 2020: Chiasma announces publication of pivotal data from the phase 3 CHIASMA OPTIMAL clinical trial in the journal of Clinical Endocrinology & Metabolism
  • Jul 27, 2020: Chiasma announces 48-week safety and efficacy data from the open-label extension study of its CHIASMA OPTIMAL phase 3 trial evaluating MYCAPSSA in patients with acromegaly
  • Jul 08, 2020: Crinetics Pharmaceuticals receives orphan drug designation for Paltusotine for the treatment of acromegaly
  • Jul 02, 2020: Camargo client Chiasma receives FDA approval for first and only oral somatostatin analog for long-term maintenance treatment of acromegaly
  • Jun 26, 2020: Chiasma announces FDA approval of MYCAPSSA (Octreotide) capsules, the first and only oral somatostatin analog
  • Jun 11, 2020: Crinetics Pharmaceuticals confirms completion for half of the enrolled patients in the ongoing phase 2 ACROBAT edge clinical trial for Paltusotine
  • Apr 06, 2020: Crinetics Pharmaceuticals reports positive interim results for the ACROBAT Edge phase 2 trial of Paltusotine (CRN00808) in acromegaly patients and provides corporate update
  • Jan 13, 2020: Chiasma announces FDA acceptance of MYCAPSSA New Drug Application Resubmission
  • Aug 26, 2019: Acromegaly early access program - status update
  • Jul 23, 2019: Chiasma announces positive phase 3 top-line results from CHIASMA OPTIMAL clinical trial of Mycapssa for the maintenance treatment of adults with Acromegaly
  • Jun 27, 2019: Chiasma provides update on ongoing Mycapssa phase 3 clinical trials
  • Jun 20, 2019: Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
  • Jun 05, 2019: Chiasma strengthens leadership team ahead of anticipated commercial availability of Mycapssa
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.